Akari Therapeutics Plc
Akari Therapeutics Plc (AKTX): 6 pipeline candidates · ~4 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.7 months
D/E 1.36 · 30% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for Akari Therapeutics Plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$20.7M
Cash
$2.8M
Quarterly Burn
$2.5M
Runway
3.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$200K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 38,922 | $200K |
| morgan stanley | 1 | $5 |
| truvestments capital llc | 1 | $5 |
Frequently asked questions
How many drug candidates are in Akari Therapeutics Plc's pipeline?
Akari Therapeutics Plc (AKTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Akari Therapeutics Plc's lead drug candidate?
Akari Therapeutics Plc's most advanced tracked candidate is aktx-101 (Preclinical) for Solid tumors (including lung, breast, urothelial, gastric, pancreatic, and others).
What is Akari Therapeutics Plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Akari Therapeutics Plc has approximately 3.7 months of cash runway.
What is Akari Therapeutics Plc's market capitalization?
Akari Therapeutics Plc's market capitalization is approximately $20.7M.
Who is the CEO of Akari Therapeutics Plc?
Mr. Abizer Gaslightwala is the chief executive officer of Akari Therapeutics Plc (AKTX).
Get the full picture on Akari Therapeutics Plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.